Combined Treatment with Epimedium koreanum Nakai Extract and Gefitinib Overcomes Drug Resistance Caused by T790M Mutation in Non-Small Cell Lung Cancer Cells

REFERENCES

• Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, et al.: Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 105, 595–605, 2013.
   PubMed Web of Science ®Google Scholar
• Antonicelli A, Cafarotti S, Indini A, Galli A, Russo A, et al.: EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. Int J Med Sci 10, 320–330, 2013.
   PubMed Web of Science ®Google Scholar
• Pao W and Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10, 760–774, 2010.
   PubMed Web of Science ®Google Scholar
• Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, et al.: Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 28, 357–360, 2010.
   PubMed Web of Science ®Google Scholar
• Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, et al.: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105, 2070–2075, 2008.
   PubMed Web of Science ®Google Scholar
• Yin JY and Chen HF: Research advances in the mechanisms of antitumor activity of Epimedium brevicornum Maxim. and its effective components. Zhong Xi Yi Jie He Xue Bao 7, 1184–1187, 2009.
   PubMedGoogle Scholar
• Wang T, Zhang JC, Chen Y, Huang F, Yang MS, et al.: Comparison of antioxidative and antitumor activities of six flavonoids from Epimedium koreanum. Zhongguo Zhong Yao Za Zhi 32, 715–718, 2007.
   PubMedGoogle Scholar
• Cheng Y, Wang XL, Zhang DW, Wang NL, and Yao XS: Nonflavanoid compounds from Epimedium koreanum. Chinese Traditional and Herbal Drugs 38, 1135–1138, 2007.
   Google Scholar
• Yu X, Tong Y, Han XQ, Kwok HF, Yue GG, et al.: Anti-angiogenic activity of Herba Epimedii on zebrafish embryos in vivo and HUVECs in vitro. Phytother Res 12,1368–1375, 2012.
   Google Scholar
• Li Q, Huai L, Zhang C, Wang C, Jia Y, et al.: Icaritin induces AML cell apoptosis via the MAPK/ERK and PI3K/AKT signal pathways. Int J Hematol 97, 617–623, 2013.
   PubMed Web of Science ®Google Scholar
• Wu J, Zuo F, Du J, Wong PF, Qin H, et al.: Icariside II induces apoptosis via inhibition of the EGFR pathways in A431 human epidermoid carcinoma cells. Mol Med Rep 8, 597–602, 2013.
   PubMed Web of Science ®Google Scholar
• Cassileth BR, Rizvi N, Deng G, Yeung KS, Vickers A, et al.: Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients. Cancer Chemother Pharmacol 65, 67–71, 2009.
   PubMed Web of Science ®Google Scholar
• Liu JPM, Li Y, Ye D, Guo Y, and Li Y: Clinical study of oral liquid Jin Fu Kang for the treatment of primary non-small cell lung cancer. Tumor (Shanghai) 21, 463–465, 2001.
   Google Scholar
• Chou TC and Talalay P: Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22, 27–55, 1996.
   Google Scholar
• Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, et al.: Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 83, 425–432, 2007.
   PubMed Web of Science ®Google Scholar
• Song J, Xu H, Lu Q, Xu Z, Bian D, et al.: Madecassoside suppresses migration of fibroblasts from keloids: involvement of p38 kinase and PI3K signaling pathways. Burns 38, 677–684, 2012.
   PubMed Web of Science ®Google Scholar
• Song J, Shu L, Zhang Z, Tan X, Sun E, et al.: Reactive oxygen species-mediated mitochondrial pathway is involved in Baohuoside I-induced apoptosis in human non-small cell lung cancer. Chem Biol Interact 199, 9–17, 2012.
   PubMed Web of Science ®Google Scholar
• Rho JK, Cho i YJ, Lee JK, Ryoo BY, Na II, et al.: The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor s. Mol Cancer Res 7, 1736–1743, 2009.
   PubMed Web of Science ®Google Scholar
• Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9, 265–273, 2009.
   PubMed Web of Science ®Google Scholar
• Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, et al.: Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29, 2346–2356, 2010.
   PubMed Web of Science ®Google Scholar
• Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, et al.: Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res 16, 174–183, 2010.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Cui ZY, Zhang L, and Li SZ: Inhibition of Icariin on several tumor cell proliferation by MTT assay. Shanghai J Immunol 15, 167–168, 1995.
   Google Scholar
• Hong J, Zhang Z, Lv W, Zhang M, Chen C, et al.: Icaritin synergistically enhances the radiosensitivity of 4T1 breast cancer cells. PLoS One 8, e71347, 2013.
   PubMed Web of Science ®Google Scholar
• Rho JK, Choi YJ, Jeon BS, Choi SJ, Cheon GJ, et al.: Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Mol Cancer Ther 9, 3233–3243, 2010.
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ, Tebbutt NC, and Mariadason JM: Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway. Curr Cancer Drug Targets 10, 824–833, 2010.
   PubMed Web of Science ®Google Scholar
• Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, et al.: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25, 2053–2059, 2004.
   PubMed Web of Science ®Google Scholar
• Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, et al.: Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 16, 5489–98, 2010.
   PubMed Web of Science ®Google Scholar
• Engelman JA and Jänne PA: Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14, 2895–2899, 2008.
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, Zakowski MF, Miller VA, Scher HI, and Kris MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6, 4885–4892, 2000.
   PubMed Web of Science ®Google Scholar
• Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, et al.: Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. PLoS One 6, e23756, 2011.
   PubMed Web of Science ®Google Scholar